The phase III IMpower150 trial (NCT02366143) evaluates atezolizumab (anti-PD-L1) combined with carboplatin/paclitaxel ± bevacizumab versus standard chemotherapy in Stage IV nonsquamous non-small cell lung cancer (NSCLC), demonstrating that PD-L1/vascular endothelial growth factor (VEGF) dual targeting improves PFS in high-tumor mutational burden subgroups (arm B: 9.7 vs arm C: 6.1 months, HR = 0.62) [174–176]. Here, CD274 is linked to non-small cell lung carcinoma.